Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD’s unique NMR technology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-c4xd-enter-collaboration-to-identify-pre-clinical-development-candidates-for-stress-related-addictive-disorder-programme-5265